Open access
Open access
Powered by Google Translator Translator

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

7 Jun, 2021 | 00:01h | UTC

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial – The Lancet

Related: #ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.